BioLargo (BLGO) director receives 165,198-share option grant for board fees

Rhea-AI Filing Summary

BioLargo director Linda Park received a stock option grant as board compensation. She was awarded options to purchase 165,198 shares of common stock at an exercise price of $0.1135 per share. After this grant, she holds options covering a total of 1,546,700 shares.

The option was issued in lieu of $18,750 in cash fees for her most recent quarterly board service, under BioLargo’s 2024 Equity Incentive Plan. This is a non-cash, compensation-related award rather than an open-market stock purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Park Linda

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	165,198	$0.00	--

Holdings After Transaction: Option to Purchase Common Stock — 1,546,700 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 165,198 shares Exercise price: $0.1135 per share Fees paid in options: $18,750 +3 more

6 metrics

Option grant size 165,198 shares New option to purchase common stock granted on June 30, 2026

Exercise price $0.1135 per share Conversion or exercise price for the granted options

Fees paid in options $18,750 Board fees converted into option grant for most recent quarter

Total options after grant 1,546,700 shares Total derivative holdings following this transaction

Grant code Transaction code A Classified as grant, award, or other acquisition

Expiration date June 30, 2036 Option expiration for the granted derivative

Key Terms

Option to Purchase Common Stock, Grant, award, or other acquisition, 2024 Equity Incentive Plan, derivative

4 terms

Option to Purchase Common Stock financial

"security_title: "Option to Purchase Common Stock""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

2024 Equity Incentive Plan financial

"pursuant to the Issuer's 2024 Equity Incentive Plan."

derivative financial

"transaction_type: "derivative""

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 06:42 PM Accepted by SEC EDGAR 07/02/2026 - 06:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Park Linda

(Last) (First) (Middle)

14921 CHESTNUT ST.

(Street)

WESTMINSTER CALIFORNIA 92683

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOLARGO, INC. [ BLGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$0.1135	06/30/2026		A		165,198		06/30/2026	06/30/2036	Common Stock	165,198	(1)	1,546,700	D

Explanation of Responses:

1. This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan. The number of shares in the Option is equal to the amount of fees due divided by the exercise price of the Option.

	/s/ John R. Browning, attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BioLargo (BLGO) director Linda Park report in this Form 4?

Director Linda Park reported receiving a stock option grant for 165,198 shares as board compensation. The options are tied to her most recent quarterly service and were issued instead of cash fees, under BioLargo’s 2024 Equity Incentive Plan.

How many BioLargo (BLGO) shares are covered by Linda Park’s new option grant?

The new option grant covers 165,198 shares of BioLargo common stock. These options are exercisable at a fixed price and represent non-cash compensation for her latest quarter of board service in accordance with the company’s 2024 Equity Incentive Plan.

What is the exercise price of Linda Park’s BioLargo (BLGO) stock options?

The exercise price of the options is $0.1135 per share. This means she can buy BioLargo common stock at that price under the terms of the grant, subject to the option’s exercise and expiration dates specified in the award.

How many BioLargo (BLGO) options does Linda Park hold after this grant?

After the reported grant, Linda Park holds options covering 1,546,700 shares of BioLargo common stock. This total reflects her derivative ownership following the new award, as disclosed in the Form 4 transaction details.

Was Linda Park’s BioLargo (BLGO) option grant a cash transaction?

No, the option grant was not a cash transaction. It was issued in payment of $18,750 in fees owed for her quarterly board service, effectively converting cash compensation into equity under the 2024 Equity Incentive Plan.